Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Three-Drug cocktail clear a stubborn lung infection?

NCT ID NCT05906316

Disease control Sponsor: Radboud University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 15, 2026 · Last updated Sep 16, 2026 · Updated 1 time

Summary

Researchers are following 100 people newly diagnosed with Mycobacterium avium complex pulmonary disease (MAC-PD) who need standard three-drug antibiotic treatment. The study measures how many patients clear the infection after six months, how their bacterial load changes, and how their symptoms shift. It also tracks whether patients stick to the regimen and whether doctors need to adjust it. The goal is to understand how well guideline-based therapy works in real-world settings.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
guideline-based three-drug antimycobacterial therapy
What this could lead to
If the three-drug regimen clears infections as expected, the findings could help doctors refine how they treat MAC lung disease and set realistic expectations for patients.
What could go wrong
This is an observational cohort, not a randomized trial, so it cannot prove the drugs cause any particular outcome. Some patients may not clear the infection, and the antibiotics can cause side effects that make it hard to stay on treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2023

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with Mycobacterium avium complex pulmonary disease that (MAC-PD) requires guideline-based three-drug antimycobacterial therapy. MAC is the most common causative species of pulmonary NTM infections.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Newly diagnosed MAC-PD (primary or recurrent) as per the international NTM guideline that requires three-drug antimycobacterial treatment * Signed and dated informed consent Exclusion Criteria: * The participant is in poor general condition where participation in the study cannot be accepted per discretion of the Investigator * The participant has a known or suspected, current drug or alcohol abuse, that is, in the opinion of the Investigator, sufficient to compromise the safety or cooperation of the patient * HIV-infection; * Cystic fibrosis; * \>1 month antibiotic treatment for current MAC infection; * \< 6 months between previous antimycobacterial NTM-PD treatment and antimycobacterial treatment for current MAC-PD * Disseminated MAC infection; * Active pulmonary tuberculosis, fungal or nocardial disease requiring treatment; * Active pulmonary malignancy (primary or metastatic) or any other malignancy requiring chemotherapy or radiotherapy within 6 months before screening or anticipated during the study period;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mycobacterium avium complex pulmonary disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Mycobacterium avium complex disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mycobacterium avium complex pulmonary disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites in 10 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aarhus University Hospital

    RECRUITING

    Aarhus, Denmark

  • Fukujuji Hospital

    RECRUITING

    Tokyo, Japan

  • Hospital Clínic de Barcelona

    RECRUITING

    Barcelona, Spain

  • Oregon Science and Health University

    RECRUITING

    Portland, Oregon, 97239, United States

  • Radboud University Medical Center

    RECRUITING

    Nijmegen, 6511LK, Netherlands

  • Rasmus Rude Laub

    RECRUITING

    Hellerup, Denmark

  • Seoul National University Hospital

    RECRUITING

    Seoul, South Korea

  • UZ Leuven

    RECRUITING

    Leuven, Belgium

  • University Hospital Center Zagreb

    RECRUITING

    Zagreb, Croatia

  • University Hospital Frankfurt

    RECRUITING

    Frankfurt, Germany

  • University of Calgary

    RECRUITING

    Calgary, Alberta, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.